RET and hepatocellular carcinoma: Anti-VEGF treatment increases survival and is the standard-of-care for hepatocellular carcinoma (HCC), with sorafenib (VEGFR2, PDGFR, Raf1 inhibitor), lenvatinib (VEGFR, FGFR, c-Kit and RET inhibitor) and regorafenib (VEGFR2, Tie2 inhibitor) being common treatments [81,82].